Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A Bayesian adaptive phase II clinical trial design accounting for spatial variation.

Guo B, Zang Y.

Stat Methods Med Res. 2018 Sep 19:962280218797149. doi: 10.1177/0962280218797149. [Epub ahead of print]

PMID:
30229695
2.

Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy.

Shiue K, Cerra-Franco A, Shapiro R, Estabrook N, Mannina EM, Deig CR, Althouse S, Liu S, Wan J, Zang Y, Agrawal N, Ioannides P, Liu Y, Zhang C, DesRosiers C, Bartlett G, Ewing M, Langer MP, Watson G, Zellars R, Kong FM, Lautenschlaeger T.

J Thorac Oncol. 2018 Oct;13(10):1549-1559. doi: 10.1016/j.jtho.2018.06.007. Epub 2018 Jun 27.

PMID:
29959060
3.

An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.

Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM, Troncoso P, DePinho RA, Wang YA.

Cancer Res. 2018 Jul 15;78(14):3823-3833. doi: 10.1158/0008-5472.CAN-17-3564. Epub 2018 May 16.

PMID:
29769196
4.

IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.

Wang W, Huang L, Jin JY, Jolly S, Zang Y, Wu H, Yan L, Pi W, Li L, Mellor AL, Kong FS.

Cancer Res. 2018 Feb 1;78(3):809-816. doi: 10.1158/0008-5472.CAN-17-2995. Epub 2017 Nov 8.

PMID:
29118088
5.

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R.

Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4.

PMID:
28978636
6.

Substantial hepatic necrosis is prognostic in fulminant liver failure.

Ndekwe P, Ghabril MS, Zang Y, Mann SA, Cummings OW, Lin J.

World J Gastroenterol. 2017 Jun 21;23(23):4303-4310. doi: 10.3748/wjg.v23.i23.4303.

7.

Optimal sequential enrichment designs for phase II clinical trials.

Zang Y, Yuan Y.

Stat Med. 2017 Jan 15;36(1):54-66. doi: 10.1002/sim.7128. Epub 2016 Sep 19.

8.

A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.

Zang Y, Lee JJ.

Stat Med. 2017 Jan 15;36(1):27-42. doi: 10.1002/sim.7082. Epub 2016 Aug 18.

9.

Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine.

Braun Hashemi CA, Zang YC, Arbona JA, Bauerle JA, Frazer ML, Lee H, Flury L, Moore ES, Kolar MC, Washington RY, Kolar OJ.

Mult Scler. 2006 Oct;12(5):652-8.

PMID:
17086913

Supplemental Content

Loading ...
Support Center